List view / Grid view
24 September 2014 | By Gilead
Gilead Sciences, Inc. announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives...
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s U.S. regulatory approval.
27 June 2014 | By Gilead
If approved, sofosbuvir would be the first all-oral treatment regimen for patients in Japan with genotype 2 HCV...
29 April 2014 | By Gilead
Gilead Sciences, Inc. announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi® (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus...
28 March 2014 | By Gilead Sciences
If approved, once-daily tablet would simplify therapy and eliminate need for Interferon and Ribavirin for Genotype 1 Hepatitis C patients in Europe...
8 December 2013 | By Gilead Sciences
In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months...
2 November 2013 | By Creston Health
“The VALENCE results demonstrate the high efficacy of a 24-week, sofosbuvir-based, interferon-free treatment regimen for genotype 3 HCV patients..."
16 October 2013 | By Gilead
Long-term data in treatment-naïve patients highlight Stribild’s sustained efficacy, safety and tolerability profile...
9 October 2013 | By Gilead
"We are pleased that idelalisib has shown a clinically meaningful benefit for patients..."
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
11 September 2013 | By Gilead Sciences
Gilead Sciences, Inc. has submitted a NDA to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of iNHL...
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
17 June 2013 | By Gilead Sciences, Inc.
Gilead Sciences announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib...
7 June 2013 | By Gilead Sciences
Gilead Sciences announced that the U.S. FDA has granted priority review...
